German Pharmaceutical Law Removes Incentives For Orphan Drug R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
National biotechnology and pharmaceutical industry associations object to certain provisions in the proposed German law on restructuring the pharma sector, AMNOG, that would add health technology assessments for orphan drugs.